TBRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TruBridge Inc (TBRG) is not a good buy for a beginner, long-term investor at this time. The stock faces significant negative catalysts, including legal investigations, delayed financial reporting, and declining revenue. Additionally, technical indicators suggest the stock is overbought, and the options data reflects limited bullish sentiment. While there are no strong buy signals from Intellectia Proprietary Trading Signals, the overall sentiment and financial performance do not align with a favorable long-term investment opportunity.
The MACD histogram is positive at 0.488 and expanding, indicating bullish momentum. However, the RSI is at 80.955, signaling the stock is overbought. Moving averages are converging, suggesting indecision in price movement. The stock is trading near resistance levels (R1: 17.618, R2: 18.626), which may limit further upside in the short term.
The company's Q4 EBITDA exceeded consensus by 7.3%, and management completed its year-end audit procedures with no material impact on 2025 results. Analysts note a strengthening pipeline, which could support modest revenue growth.
The company is under investigation for allegedly issuing misleading business information. It has delayed its annual financial report due to errors in prior financial statements, leading to a significant drop in stock price. A class action lawsuit is being prepared against the company. Revenue declined by 3.35% YoY in Q4 2025, and gross margin dropped by 1.16% YoY. Analysts have lowered price targets, and the company has not provided 2026 guidance due to an ongoing strategic review.
In Q4 2025, revenue decreased by 3.35% YoY to $87.79 million. Net income improved to -$4.14 million, up 40.89% YoY, and EPS increased to -$0.28, up 40% YoY. However, gross margin dropped to 46.84%, down 1.16% YoY, reflecting operational challenges.
Analysts have mixed views. Deutsche Bank raised its price target to $23 but maintained a Hold rating. Stephens and BMO Capital lowered their price targets to $18 and $15, respectively, citing concerns over the company's strategic review and modest revenue growth outlook.
